Drug Profile
Research programme: MEK inhibitors - Atriva Therapeutics
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator University of Muenster
- Developer Atriva Therapeutics
- Class Antibacterials; Antivirals
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Influenza virus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Bacterial-infections in Germany
- 28 Aug 2020 No recent reports of development identified for research development in Influenza-virus-infections in Germany
- 04 Nov 2016 Atriva Therapeutics receives patent allowance for MEK inhibitors in USA